Although cannabinoids exhibit a broad variety of anticarcinogenic effects, their potential use in cancer therapy is limited by their psychoactive effects. Here we evaluated the impact of cannabidiol, a plant-derived non-psychoactive cannabinoid, on cancer cell invasion. Using Matrigel invasion assays we found a cannabidiol-driven impaired invasion of human cervical cancer (HeLa, C33A) and human lung cancer cells (A549) that was reversed by antagonists to both CB 1 and CB 2 receptors as well as to transient receptor potential vanilloid 1 (TRPV1). Additionally, in vivo studies in thymic-aplastic nude mice revealed a significant inhibition of A549 lung metastasis in cannabidiol-treated animals as compared to vehicle-treated controls.
Introduction
During the last decade several cell culture and animal studies have provided a great body of evidence for an antitumorigenic action of cannabinoids on the levels of cancer cell proliferation [1, 2] , apoptosis [3, 4] , metastasis [5] , and angiogenesis [6] [7] [8] . Although cannabinoid-based drugs such as ∆ 9 -tetrahydrocannabinol (THC) are clinically used to palliate wasting, emesis and pain in cancer patients, a shortcoming for these and forthcoming indications clearly lies in the psychoactive adverse side effects of cannabinoids.
For this reason, the interest in the non-psychoactive cannabinoid-mimetic compound cannabidiol has substantially increased in recent years. Meanwhile, a formulation including a 1:1 ratio of THC and cannabidiol has been approved for the pharmacotherapy of multiple sclerosis-related spasticity and pain in Canada [9] .
The precise mechanism by which cannabidiol exerts its biological effects is still a matter of debate. Although cannabidiol displays a low affinity to CB 1 and CB 2 receptors [10] , several effects of cannabidiol including modulation of cytokine release and macrophage chemotaxis [11] , antiproliferative [12] as well as proapoptotic properties [13] have been shown to be mediated via CB 1 and/or CB 2 receptors. In other investigations, cannabidiol has even been reported to display antagonistic effects on CB 1 and CB 2 receptor [14] , as well as synergistic effects on THC-mediated hypoactivity, hypothermia and impairment of spatial memory [15] .
On the other hand increasing evidence suggests an indirect receptor activation by cannabidiol. In this context an inhibitory action on fatty acid amidohydrolase activity that confers release of anandamide and increased receptor-mediated signalling by this endocannabinoid has been demonstrated in diverse systems [16] [17] [18] . Additionally, the nonselective cation channel transient receptor potential 1 (TRPV1) was shown to be involved in cannabidiol-mediated antihyperalgesia [19] and inhibition of cancer cell proliferation [17] .
Finally, diverse studies suggest the involvement of a hitherto undefined abnormal cannabidiol receptor in several actions of cannabidiol (for review see [20] ). 5 In context with the antitumorigenic action of cannabinoids, modulation of cancer cell invasion has recently emerged as a topic of increasing interest [21] [22] [23] . Cancer cell invasion is a complex process of cell locomotion through degraded matrix components of microenvironmental spaces surrounding a tumor thereby contributing to tumor cell metastasis and angiogenesis. The level of tumor invasiveness and malignancy is mainly determined by a sensitive balance between collagen-and proteoglycan-degrading matrix metalloproteinases (MMPs) and their endogenous inhibitors, the tissue inhibitors of MMPs (TIMPs) (for review see ref. [24] ). Among the four distinct members of the TIMP family, elevated TIMP-1 was shown to mediate the anti-invasive effects of several anticarcinogenic drugs [23, [25] [26] [27] [28] [29] . Furthermore, decreased TIMP-1 levels were demonstrated to correlate with high cancer invasiveness [30, 31] .
The present study focussed on a potential role of TIMP-1 upregulation in the anti-invasive action of cannabidiol and on a possible involvement of cannabinoid receptors and TRPV1 in this process. In view of recent studies demonstrating p38 and p42/44 mitogen-activated protein kinases (MAPK) activation as intracellular signaling pathways leading to induction of TIMP-1 [32, 33] as well as findings showing a cannabinoid receptor-dependent activation of MAPKs [3, 34, 35] , our study also assessed a role of both MAPKs in cannabidiol-modulated invasion and TIMP-1 expression. Finally, the impact of cannabidiol on cellular invasion was confirmed by studying metastasis in vivo. 7 insert in 24-well plates. Trypsinized and pelleted cells were suspended to a final concentration of 5 x 10 5 cells in 500 µl serum-free DMEM in each insert and treated with a final concentration of 10 µM cannabidiol (except Figure 1B and the data in Table 2 ) or ethanol vehicle for various incubation times. In Table 2 (Fig. 3C ), HeLa cells that had invaded through Matrigel-coated membranes were fixed and stained with Diff-Quick (Medion Diagnostics GmbH, Dügingen, Switzerland) and visualized using a microscope at 200 x magnification.
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Quantitative RT-PCR analysis
HeLa cells were seeded into 48-well plates at a density of 5 x 10 5 cells per well. Following incubation of cells with cannabidiol or its vehicle for the indicated times, supernatants were removed and cells were lysed for subsequent RNA isolation using the RNeasy total RNA Kit (Qiagen, Hilden, Germany). β-Actin-(internal standard) and TIMP-1 mRNA levels were determined by quantitative real-time RT-PCR as described [36] . Primers and probe for human TIMP-1 was an Assay-on-demand™-product (Applied Biosystems, Darmstadt, Germany).
Western blot analysis
For determination of TIMP-1, MMP-2 and MMP-9 protein levels in Fig. 2B , cells grown to A c c e p t e d M a n u s c r i p t Subsequently, cells were treated with trypsin for 3 minutes at 37°C in a humidified incubator, centrifuged at 200 x g, resuspended to a final density of 5 x 10 5 cells in 500 µl of serum-free DMEM containing the same amounts of siRNA or non-silencing siRNA to provide constant transfection conditions, and seeded for invasion analysis as described above.
Mouse model of tumor metastasis
Athymic nude mice (NMRI-nu/nu) were purchased from Charles River GmbH (Sulzfeld, Germany). Mice were given injections of A549 cells (1 x 10 6 per 100 µl in PBS) through the lateral tail vein (day 1) and, after 24 hours (day 2), were treated with cannabidiol (5 mg/kg body weight) or with vehicle intraperitoneally. Treatment protocols for the evaluation of the antitumorigenic action of cannabidiol in vivo developed by other groups revealed 5 mg cannabidiol per kg as an appropriate dose for this purpose [17] . In our experiments cannabidiol or vehicle were administered every 72 hour. Mice were sacrificed on day 28 and one lung per animal was evaluated for experimental metastases. To contrast lung nodules, lungs were fixed in Bouin´s fluid (picrinic acid 15 ml, formol 5 ml, acetate 1 ml), and metastatic nodes were scored under a stereoscopic microscope in an investigator-blinded 
Statistics
All statistical analyses were undertaken using GraphPad Prism 3.00 (GraphPad Software, San Diego, CA). Results were considered to be statistically significant at P < 0.05.
To assess the half maximal effective concentration (EC 50 ) of cannabidiol in eliciting an antiinvasive response, concentration response curves were fitted by a log(agonist) vs.
response regression with variable slope.
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Results

Time-course and concentration-dependency of cannabidiol´s inhibitory effect on HeLa cell invasion
HeLa cells showed a diminished invasion within the first 24 hours of incubation with 10 µM cannabidiol that continued to increase over the investigated 72-hour incubation period ( (Table 1) .
To confirm the antiinvasive action of cannabidiol in another experimental setup, additional experiments were performed with HeLa cells that were first treated with cannabidiol or vehicle for 48 hours and trypsinized, counted and adjusted to a final cellular density of 0. 2C ). Furthermore, cannabidiol-induced TIMP-1 expression was abrogated by the TRPV1 antagonist capsazepine (Fig. 2C) .
Effect of TIMP-1 knockdown on the anti-invasive action of cannabidiol
To further confirm a causal link between cannabidiol-mediated TIMP-1 induction and the accompanied decreased invasion, the expression of TIMP sequences elicited an invasive behavior comparable to controls lacking siRNA. 15 
Effect of blockade of MAPK pathways on cannabidiol´s anti-invasive and TIMP-1-inducing action
In further experiments addressing the role of p38 and p42/44 MAPKs in the anti-invasive and TIMP-1-inducing action of cannabidiol, inhibitors of p38 MAPK activity (SB203580, 10 µM) and of p42/44 MAPK activation (PD98059, 10 µM) substantially inhibited both cannabidiol effects (Fig. 4A ,B, Table 2 ). As previously described, SB203580 and PD98059 alone did not modulate baseline TIMP-1 expression and Matrigel invasion of HeLa cells [29] .
Additional inhibitor experiments were performed to confirm a causal link between receptor activation and MAPK phosphorylations. As shown in Fig. 4C , cannabidiol induced activation of p38 and p42/44 MAPKs at two early time points following stimulation. According to Fig.   4D , both activations were substantially suppressed by CB 1 -and CB 2 antagonists as well as by the TRPV1 antagonist.
Role of TIMP-1 in the anti-invasive action of cannabidiol in other tumor cell lines
To exclude that the demonstrated effects are restricted to HeLa cells, experiments were also performed in human lung carcinoma cells (A549, Fig. 5 ) and in another human cervical carcinoma cell line (C33A, Fig. 6 ).
Like in HeLa cells, addition of cannabidiol resulted in a profound suppression of invasion through Matrigel-coated transwell plates in A549 (Fig. 5 ) and C33A cells (Fig. 6 ). Decreased invasiveness was accompanied by increased TIMP-1 secretion with both events being significantly suppressed by a 1-hour preincubation with antagonists of CB 1 (AM-251, 1 µM) and CB 2 receptors (AM-630, 1 µM) alone or in combination and by a TRPV1 antagonist (capsazepine, 1 µM) in A549 (Fig. 5A ) and C333A cells (Fig. 6A) .
Furthermore, in both cell lines the blockade of p38 or p42/44 pathways led to a significant reconstitution of the cannabidiol-mediated decrease of Matrigel invasion ( Fig. 5B and 6B ).
Like in HeLa cells, TIMP-1 levels in cell culture supernatants of the upper transwell inserts revealed an inverse correlation between invasiveness and TIMP-1 levels ( Fig. 5B and 6B ).
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Impact of cannabidiol on lung metastases
We further investigated the impact of cannabidiol on tumor cell metastasis in vivo in a mouse model. For this purpose, A549 cells were injected intravenously through the lateral tail vein of athymic nude mice. According to Fig. 7 , the number of lung metastatic nodules was significantly lower in cannabidiol-treated animals as compared to vehicle-treated controls.
The decrease of nodules was from an average of 6 nodules in vehicle-treated nude mice to an average of 1 nodule in cannabidiol-treated mice yielding an 84% inhibition of metastasis.
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Discussion
An increasing number of data obtained both in vivo and in vitro implicates a possible role for cannabinoids as systemic cancer therapeutics. Although cannabinoids virtually lack side effects of contemporarily used anticancer drugs such as chemotherapeutics-induced emesis and collateral toxicity, cannabinoids´ therapeutical use is limited by their psychotropic side effects. Therefore, recent research focussed on non-psychoactive cannabinoid-mimetic compounds such as cannabidiol.
In the present study we identified a cannabinoid receptor-and TRPV1-triggered expression of TIMP-1 as an important mediator of the anti-invasive action of cannabidiol. Cannabidiol was shown to decrease HeLa cell invasion in a time-and concentration-dependent manner.
Following a 72-hour incubation period, the decreased invasiveness was significant at a cannabidiol concentration as low as 0.01 µM which elicited a 33% inhibition when compared to vehicle control. Although this effect was less pronounced as compared to an equimolar concentration of THC which yielded a 68% inhibition of invasion in the same experimental setup [23] , the anti-invasive effects of cannabidiol described here occurred in a range of therapeutically relevant concentrations. Accordingly, referring to clinical data on healthy volunteers obtained from studies with Sativex™ (1:1 ratio of THC and cannabidiol) applied at a 10-mg buccal dose or at self-titrated doses during chronic therapy, cannabidiol peak plasma concentrations of 0.01 µM or up to 0.05 µM can be achieved in vivo [38] . Moreover, mean cannabidiol plasma levels of 0.036 µM were analyzed following a 6-week oral treatment with cannabidiol at doses of 10 mg/kg/day [39] .
With reference to a number of data reporting an anti-invasive effect of TIMP-1 on cancer cell invasion [23, [25] [26] [27] [28] [29] [30] [31] , the present work focussed on the causal link of cannabinoid receptor- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 An invasion-associated effect that is mainly determined by the ability of cancer cells to secrete matrix-degrading enzymes or to modulate their activity rather than on cellular motility was substantiated by the finding that reduced Matrigel invasion was not associated with a decrease of transmigration through uncoated Boyden chambers after cannabidiol treatment.
To rule out the possibility that decreased invasion by cannabidiol was an unspecific cytotoxicity-related phenomenon, control experiments were also performed to analyse cellular viability which revealed no significant cytotoxicity by cannabidiol under conditions of the experimental set-up of invasion monitoring. In line with recent data obtained with THC and R(+)-methanandamide [23] , cannabidiol showed a significant and progressive toxicity only when the density of HeLa, A549 and C33A cells was reduced. Such "inoculum effect"
has been described for a number of chemotherapeutic drugs such as tamoxifen [40] , doxorubicin and vincristine [41] . Kobayashi et al. [41] demonstrated that at high cell densities, a decreased cellular uptake of chemotherapeutics results in attenuated availability 19 of drug molecules at its intracellular binding sites. Finally, the antiinvasive effect of cannabidiol was confirmed to be comparable in another experimental setting, where HeLa cells treated with cannabidiol or vehicle for 48 hours were readjusted to equal numbers of cells prior to the 24-hour incubation in Matrigel inserts.
There are several issues raised in this study that have to be addressed in future experiments. First, the effect of cannabidiol on TIMP-1 was specific in that the expression of other regulable components of this systems, i.e. MMP-2 and MMP-9, were not influenced by cannabidiol on the level of protein expression. This finding stands in contrast to a recent study from our laboratory reporting a cannabinoid receptor-independent downregulation of MMP-2 by THC and R(+)-methanandamide [23] . Second, in view of the low affinity of cannabidiol to either CB 1 and CB 2 receptors [10] , the involvement of cannabinoid receptors in the anti-invasive and TIMP-1-stimulatory action of cannabidiol was rather surprising.
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